Back to Search
Start Over
Anti-tumor activity of metformin: from metabolic and epigenetic perspectives
- Source :
- Oncotarget
- Publication Year :
- 2016
- Publisher :
- Impact Journals, LLC, 2016.
-
Abstract
- // Xilan Yu 1, * , Wuxiang Mao 1, * , Yansheng Zhai 1 , Chong Tong 1 , Min Liu 1 , Lixin Ma 1 , Xiaolan Yu 1 , Shanshan Li 1 1 Hubei Collaborative Innovation Center for Green Transformation of Bio-Resources, College of Life Sciences, Hubei University, Wuhan, Hubei, China * These authors have equally contributed to this work Correspondence to: Xiaolan Yu, email: yxiaolan@163.com Shanshan Li, email: shl@hubu.edu.cn Keywords: metformin, therapeutic targets, metabolism, epigenetic modifications Received: September 22, 2016 Accepted: November 03, 2016 Published: November 26, 2016 ABSTRACT Metformin has been used to treat type 2 diabetes for over 50 years. Epidemiological, preclinical and clinical studies suggest that metformin treatment reduces cancer incidence in diabetes patients. Due to its potential as an anti-cancer agent and its low cost, metformin has gained intense research interest. Its traditional anti-cancer mechanisms involve both indirect and direct insulin-dependent pathways. Here, we discussed the anti-tumor mechanism of metformin from the aspects of cell metabolism and epigenetic modifications. The effects of metformin on anti-cancer immunity and apoptosis were also described. Understanding these mechanisms will shed lights on application of metformin in clinical trials and development of anti-cancer therapy.
- Subjects :
- 0301 basic medicine
Oncology
medicine.medical_specialty
endocrine system diseases
epigenetic modifications
Antineoplastic Agents
Apoptosis
Review
Type 2 diabetes
Pharmacology
therapeutic targets
Epigenesis, Genetic
03 medical and health sciences
0302 clinical medicine
Neoplasms
Diabetes mellitus
Internal medicine
medicine
Humans
Epigenetics
Antitumor activity
Mechanism (biology)
business.industry
digestive, oral, and skin physiology
nutritional and metabolic diseases
medicine.disease
Metformin
Clinical trial
030104 developmental biology
Cell metabolism
030220 oncology & carcinogenesis
metformin
business
metabolism
medicine.drug
Subjects
Details
- ISSN :
- 19492553
- Volume :
- 8
- Database :
- OpenAIRE
- Journal :
- Oncotarget
- Accession number :
- edsair.doi.dedup.....7bcf8cc4f6e0c886efb88535756f91bd
- Full Text :
- https://doi.org/10.18632/oncotarget.13639